These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 26448356)

  • 1. The Relationship among COPD Severity, Inhaled Corticosteroid Use, and the Risk of Pneumonia.
    Rennard SI; Sin DD; Tashkin DP; Calverley PM; Radner F
    Ann Am Thorac Soc; 2015 Oct; 12(10):1587-9. PubMed ID: 26448356
    [No Abstract]   [Full Text] [Related]  

  • 2. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data.
    Sin DD; Tashkin D; Zhang X; Radner F; Sjöbring U; Thorén A; Calverley PM; Rennard SI
    Lancet; 2009 Aug; 374(9691):712-9. PubMed ID: 19716963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD.
    Tashkin DP
    Expert Rev Respir Med; 2010 Dec; 4(6):703-14. PubMed ID: 21128746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Steurer J
    Praxis (Bern 1994); 2018 Nov; 107(24):1355-1356. PubMed ID: 30482119
    [No Abstract]   [Full Text] [Related]  

  • 5. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results.
    Fukuchi Y; Samoro R; Fassakhov R; Taniguchi H; Ekelund J; Carlsson LG; Ichinose M
    Respirology; 2013 Jul; 18(5):866-73. PubMed ID: 23551359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of an inhaled corticosteroid/long-acting β2-agonist combination in symptomatic COPD patients in GOLD groups B and D.
    Anzueto A; Jenkins CR; Make BJ; Lindberg M; Calverley PM; Fagerås M; Postma DS; Rennard SI; Tashkin DP
    Eur Respir J; 2015 Jul; 46(1):255-8. PubMed ID: 26022947
    [No Abstract]   [Full Text] [Related]  

  • 7. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
    Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.
    Worth H; Förster K; Eriksson G; Nihlén U; Peterson S; Magnussen H
    Respir Med; 2010 Oct; 104(10):1450-9. PubMed ID: 20692140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
    Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R
    Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD.
    Morgan AR; Parker GJ; Roberts C; Buonaccorsi GA; Maguire NC; Hubbard Cristinacce PL; Singh D; Vestbo J; Bjermer L; Jögi J; Taib Z; Sarv J; Bruijnzeel PL; Olsson LE; Bondesson E; Nihlén U; McGrath DM; Young SS; Waterton JC; Nordenmark LH
    Eur J Radiol; 2014 Nov; 83(11):2093-101. PubMed ID: 25176287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids.
    O'Byrne PM; Rennard S; Gerstein H; Radner F; Peterson S; Lindberg B; Carlsson LG; Sin DD
    Respir Med; 2012 Nov; 106(11):1487-93. PubMed ID: 22902134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler.
    Chrystyn H; Safioti G; Keegstra JR; Gopalan G
    Int J Pharm; 2015 Aug; 491(1-2):268-76. PubMed ID: 26043823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD.
    Tronde A; Gillen M; Borgström L; Lötvall J; Ankerst J
    J Clin Pharmacol; 2008 Nov; 48(11):1300-8. PubMed ID: 18974284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD.
    Cazzola M; Pasqua F; Ferri L; Biscione G; Cardaci V; Matera MG
    Pulm Pharmacol Ther; 2011 Feb; 24(1):118-22. PubMed ID: 20816833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of inhaled corticosteroids in chronic obstructive pulmonary disease (COPD).
    Med Lett Drugs Ther; 2010 May; 52(1339):41-2. PubMed ID: 20508579
    [No Abstract]   [Full Text] [Related]  

  • 18. Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD.
    Sun X; He Z; Zhang J; Deng J; Bai J; Li M; Zhong X
    Pulm Pharmacol Ther; 2015 Apr; 31():111-6. PubMed ID: 25281894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled corticosteroids do not influence the early inflammatory response and clinical presentation of hospitalized subjects with COPD exacerbation.
    Crisafulli E; Guerrero M; Menéndez R; Huerta A; Martinez R; Gimeno A; Soler N; Torres A
    Respir Care; 2014 Oct; 59(10):1550-9. PubMed ID: 25074943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with maintenance budesonide and formoterol in COPD.
    Medford AR
    Eur Respir J; 2004 Dec; 24(6):1070; author reply 1070-1. PubMed ID: 15572556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.